The full name of the shingles vaccine is Recombinant Shingles Vaccine, and precautions include intravenous or intradermal injection is strictly prohibited, subcutaneous vaccination is not recommended, and 11 other items. 1. The recombinant herpes zoster vaccine needs to be equipped with medical emergency measures and testing methods to ensure that patients can be treated in time when they develop allergies. 2. Patients suffering from acute severe febrile illnesses should delay vaccination, but not if they are only suffering from mild illnesses such as colds. 3. The vaccination of patients may not produce 100% preventive protection. 4. This product is only prophylactic and cannot treat an existing disease. 5. This product should not be administered intravenously or intradermally. 6. This product is not recommended for subcutaneous inoculation. 7. Use with caution in patients with thrombocytopenia or in patients suffering from any coagulation disorder, which may lead to bleeding. 8. Patients may have a cardiac reaction to the injection, and may experience fainting both before and after vaccination, and may also have transient visual disturbances, etc. Protective measures are required. 9. Patients with a history of herpes zoster and frail patients may have a limited effect of vaccination, so the pros and cons of vaccination need to be weighed by medical personnel before vaccination. 10. The desired effect may not be achieved in immunosuppressed individuals. 11. For two to three days after vaccination, the ability to operate machinery and drive may be slightly affected, and there may be discomfort and fatigue. Recombinant shingles vaccine is mainly used for the prevention of primary chickenpox and shingles in adults aged fifty years and above. It is contraindicated in patients who are allergic to any of the components of the product, and patients are advised to follow the doctor’s instructions.